Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018

NICOLAS S. Piuzzi, M. DOMINICI, M. A.R.C. LONG, C. PASCUAL-GARRIDO, S. RODEO, J. HUARD, JÉROME GUICHEUX, R. MCFARLAND, LAURIE R. GOODRICH, STÉPHANE MADDENS, PAMELA G. ROBEY, THOMAS W. BAUER, J. O.H.N. BARRETT, F. BARRY, D. KARLI, CONSTANCE R. CHU, DANIEL J. WEISS, I. V.A.N. MARTIN, C. JORGENSEN, GEORGE F. MUSCHLER

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

The Signature Series Symposium “Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies—Promise, Facts and Fantasy” was held as a pre-meeting of the 26th International Society for Cellular Therapy (ISCT) annual congress in Montreal, Canada, May 2, 2018. This was the first ISCT program that was entirely dedicated to the advancement of cell-based therapies for musculoskeletal diseases. Cellular therapies in musculoskeletal medicine are a source of great promise and opportunity. They are also the source of public controversy, confusion and misinformation. Patients, clinicians, scientists, industry and government share a commitment to clear communication and responsible development of the field. Therefore, this symposium convened thought leaders from around the world in a forum designed to catalyze communication and collaboration to bring the greatest possible innovation and value to patients with musculoskeletal conditions.

Original languageEnglish
Pages (from-to)1381-1400
Number of pages20
JournalCytotherapy
Volume20
Issue number11
DOIs
Publication statusPublished - Nov 2018

Bibliographical note

Publisher Copyright:
© 2018

Funding

The authors thanks both the ISCT and the sponsors of the First Signature Series Symposium “Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies–Promise, Facts and Fantasy,” May 2, 2018, Montreal, Canada: Greyledge Technologies (Edwards, Colorado), MTF Biologics (Edison, New Jersey), Orthofix (Lewisville, Texas), MEdXcell (Lausanne, Switzerland), Osiris Therapeutics (Columbia, Maryland) and Angiocrine Bioscience (San Diego, California). Additionally this work was supported, in part, by the DIR, NIDCR, a part of the Intramural Research Program (IRP), NIH, DHHS (to P.G.R., ZIA DE000380). The authors thanks both the ISCT and the sponsors of the First Signature Series Symposium ?Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies?Promise, Facts and Fantasy,? May 2, 2018, Montreal, Canada: Greyledge Technologies (Edwards, Colorado), MTF Biologics (Edison, New Jersey), Orthofix (Lewisville, Texas), MEdXcell (Lausanne, Switzerland), Osiris Therapeutics (Columbia, Maryland) and Angiocrine Bioscience (San Diego, California). Additionally this work was supported, in part, by the DIR, NIDCR, a part of the Intramural Research Program (IRP), NIH, DHHS (to P.G.R., ZIA DE000380).

FundersFunder number
Angiocrine Bioscience
DIR
Intramural Research Program
National Institutes of Health
U.S. Department of Health and Human ServicesZIA DE000380
National Institute of Arthritis and Musculoskeletal and Skin DiseasesU13AR073668
National Institute of Dental and Craniofacial Research
MTF Biologics
Institut des Sciences du Cerveau de Toulouse

    ASJC Scopus Subject Areas

    • Immunology and Allergy
    • Immunology
    • Oncology
    • Genetics(clinical)
    • Cell Biology
    • Transplantation
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018'. Together they form a unique fingerprint.

    Cite this